Mineralys Therapeutics, Inc.

MLYS

Mineralys Therapeutics, Inc.

MLYS

Insider Sentiment (TTM):

Last Purchase:2026-03-30Last Sale:2026-06-30Shares Purchased (TTM):1,823,005Shares Sold (TTM):1,976,183

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:87,876,903Shares Outstanding:82,834,752Institutional Ownership Pct.:106.09%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Series B Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	0
Assets Current
Cash And Cash Equivalents At Carrying Value	138	113	173	218	102	165	114	97	68	90	49	86
Debt Securities Current	523	533	484	376	223	178	84	166	243	248	187	167
Prepaid Expense And Other Assets Current	4	6	5	6	10	11	7	4	7	8	13	12
Assets Current	666	652	661	600	335	355	205	268	318	347	249	265
Debt Securities Held To Maturity Amortized Cost Af…	-	-	-	-	-	-	-	0	0	0	2	12
Marketable Securities Noncurrent	-	-	-	-	-	-	0	-	-	-	2	-
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	-
Other Assets Noncurrent	2	0	0	0	0	0	0	0	0	0	0	0
Assets	668	653	662	600	336	355	206	268	318	347	252	278
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	2	1	3	0	0	3	2	4	1	6
Accrued Liabilities Current	18	14	13	22	19	13	14	28	27	15	10	8
Liabilities Current	19	15	15	24	22	13	15	31	28	19	10	14
Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,288	1,135	1,104	1,001	702	686	494	490	487	484	366	364
Retained Earnings Accumulated Deficit	-738	-497	-457	-425	-388	-345	-303	-254	-197	-156	-125	-100
Stockholders Equity	551	638	647	576	314	342	191	237	290	328	241	264
Liabilities And Stockholders Equity	668	653	662	600	336	355	206	268	318	347	252	278
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	88	82	82	79	66	65	50	50	50	50	41	41
Series A Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	0
Shares Outstanding	88	82	82	79	66	65	50	50	50	50	41	41

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	4.58%	-11.42%	-11.32%	-	-	-	-	-	-	-	-	-
2025	7.40%	-3.13%	-8.96%	157.59%	181.72%	202.44%	-13.48%	-19.75%	-30.58%	-0.07%	8.41%	16.71%
2024	-10.51%	-18.01%	-5.75%	-5.07%	17.33%	13.69%	-1.27%	-4.71%	-23.02%	-1.03%	16.65%	45.06%
2023	-	-	-	-	-	-	-17.71%	-1.71%	17.71%	-0.61%	3.28%	0.38%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	34.46	44.33	43.76	25.50	15.12	26.48	14.02	8.55	11.20	18.06	23.76	19.59
Quick Ratio	34.24	43.90	43.45	25.24	14.65	25.63	13.53	8.42	10.96	17.63	22.57	18.74
Working Capital	646.48M	637.75M	646.27M	576.28M	313.10M	341.12M	190.71M	236.41M	289.60M	327.62M	238.62M	251.83M
Leverage & Debt
Debt to Equity	0.04	0.02	0.02	0.04	0.07	0.04	0.08	0.13	0.10	0.06	0.04	0.05
Interest Coverage TTM	-17.50	-8.70	-10.69	-14.48	-16.51	-15.53	-13.19	-11.15	-9.06	-7.36	-6.64	-
Debt Ratio	0.03	0.02	0.02	0.04	0.07	0.04	0.07	0.12	0.09	0.06	0.04	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Per Share Metrics
Diluted EPS TTM	-4.13	-1.83	-2.29	-2.43	-2.91	-3.55	-3.66	-3.08	-2.42	-2.02	-1.99	-
Free Cash Flow Per Share TTM	-1.71	-1.65	-2.11	-1.78	-2.25	-3.62	-3.43	-2.58	-1.97	-1.95	-2.24	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Growth Metrics
Net Income Growth (1Y)	83.24%	-19.49%	-13.02%	11.82%	59.41%	107.62%	147.31%	-	-	-	-	-
EPS Growth (1Y)	41.55%	-48.33%	-37.60%	-21.10%	20.21%	75.35%	84.38%	-	-	-	-	-
Valuation Metrics
P/E TTM	-6.54	-14.78	-15.88	-15.62	-4.64	-4.48	-3.36	-3.94	-4.83	-6.38	-4.33	-
P/B TTM	4.15	3.52	3.80	4.64	2.82	2.47	3.12	2.55	1.99	1.77	1.29	1.44
Market Cap	2.29B	2.24B	2.46B	2.68B	885.56M	844.24M	597.52M	603.26M	577.47M	579.67M	311.22M	379.74M
Enterprise Value	2.15B	2.13B	2.28B	2.46B	783.77M	679.23M	483.43M	505.99M	509.61M	489.25M	261.91M	293.44M
Calculated Values
Free Cash Flow TTM	-144.82M	-136.42M	-142.43M	-125.88M	-147.24M	-192.70M	-166.41M	-128.55M	-97.36M	-87.60M	-81.17M	-
Net Debt	-138.27M	-112.78M	-172.92M	-217.60M	-101.79M	-165.01M	-114.09M	-97.27M	-67.86M	-90.42M	-49.30M	-86.30M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-30Sale

Owner: Congleton, Jon

Title: Chief Executive Officer

Shares: 75,000

Price/Share: $26.38

Value: $1,978,500.00

Shares Owned: 614,321

Relationship: Director,Officer

Ownership: Direct

2026-06-26Sale

Owner: Warren, Eric

Title: Chief Commercial Officer

Shares: 104,124

Price/Share: $25.90

Value: $2,696,811.60

Shares Owned: 38,400

Relationship: Officer

Ownership: Direct

2026-06-17Sale

Owner: Rodman, David Malcom

Title: Chief Medical Officer

Shares: 4,584

Price/Share: $25.00

Value: $114,600.00

Shares Owned: 57,095

Relationship: Officer

Ownership: Direct

2026-06-17Sale

Owner: Karydas, Daphne

Title: -

Shares: 3,000

Price/Share: $25.00

Value: $75,000.00

Shares Owned: 6,200

Relationship: Director

Ownership: Direct

2026-06-12Sale

Owner: Rodman, David Malcom

Title: Chief Medical Officer

Shares: 6,349

Price/Share: $23.93

Value: $151,931.57

Shares Owned: 63,443

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-30	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	75,000	26.38	$1,978,500.00	614,321	4
2026-06-26	Warren, Eric	Officer	Chief Commercial Officer	Direct	Sale	104,124	25.90	$2,696,811.60	38,400	4
2026-06-17	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	4,584	25.00	$114,600.00	57,095	4
2026-06-17	Karydas, Daphne	Director	-	Direct	Sale	3,000	25.00	$75,000.00	6,200	4
2026-06-12	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	6,349	23.93	$151,931.57	63,443	4
2026-05-18	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	417	27.55	$11,488.35	63,443	4
2026-05-13	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	14,056	28.58	$401,720.48	63,443	4
2026-04-17	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	416	31.33	$13,033.28	69,792	4
2026-04-15	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	6,348	27.66	$175,585.68	69,792	4
2026-04-13	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	15,730	26.83	$422,035.90	689,321	4
2026-04-09	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	2,170	27.38	$59,414.60	76,140	4
2026-03-31	Karydas, Daphne	Director	-	Direct	Sale	3,000	25.00	$75,000.00	6,200	4
2026-03-31	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	75,000	26.36	$1,977,000.00	705,051	4
2026-03-30	Shah, Rajeev M., Ra Capit…	Director	-	Indirect	Purchase	58,300	24.16	$1,408,528.00	5,825,521	4
2026-03-17	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	417	25.65	$10,696.05	76,140	4
2026-03-13	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	14,058	27.03	$379,987.74	76,140	4
2026-03-09	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	2,171	26.84	$58,269.64	82,489	4
2026-02-17	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	417	27.59	$11,505.03	44,089	4
2026-02-13	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	14,055	27.41	$385,247.55	44,089	4
2026-02-09	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	2,171	30.21	$65,585.91	50,437	4
2026-01-20	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	416	32.10	$13,353.60	50,437	4
2026-01-14	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,367	32.61	$370,677.87	50,437	4
2026-01-12	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,758	32.14	$345,762.12	8,638	4
2026-01-12	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	16,236	32.68	$530,592.48	639,151	4
2026-01-12	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	6,348	32.32	$205,167.36	61,804	4
2026-01-05	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	192,715	35.18	$6,779,713.70	61,804	4
2025-11-20	Catalys, Pacific Fund, Lp…	Director,TenPercentOwner	-	Indirect	Sale	1,000,000	43.35	$43,350,000.00	7,903,838	4
2025-11-13	Karydas, Daphne	Director	-	Direct	Sale	15,000	46.08	$691,200.00	0	4
2025-11-13	Gold, Alexander M	Director	-	Direct	Sale	12,742	46.50	$592,503.00	0	4
2025-11-11	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	119,524	43.56	$5,206,465.44	19,396	4
2025-11-11	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	200,000	44.23	$8,846,000.00	631,305	4
2025-10-15	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	10,369	43.01	$445,970.69	71,155	4
2025-10-13	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	15,100	42.83	$646,733.00	831,305	4
2025-10-13	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,758	42.08	$452,696.64	116,865	4
2025-09-15	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,367	36.18	$411,258.06	81,524	4
2025-09-04	Akkaraju, Srinivas	Director	-	Indirect	Purchase	588,235	25.50	$14,999,992.50	588,235	4
2025-09-04	Ra, Capital Management, L…	Director	-	Indirect	Purchase	1,176,470	25.50	$29,999,985.00	5,456,521	4
2025-08-13	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,365	12.93	$146,949.45	92,891	4
2025-07-30	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	59,925	14.90	$892,882.50	132,934	4
2025-07-14	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,366	14.59	$165,829.94	97,907	4
2025-07-11	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,758	14.45	$155,453.10	206,612	4
2025-07-11	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	15,884	14.51	$230,476.84	846,405	4
2025-06-13	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,366	14.60	$165,943.60	101,651	4
2025-05-14	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,366	15.29	$173,786.14	106,669	4
2025-04-14	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	11,366	14.26	$162,079.16	111,686	4
2025-04-11	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	15,319	12.19	$186,738.61	862,289	4
2025-04-11	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,757	12.06	$129,729.42	215,340	4
2025-04-01	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	55,771	15.93	$888,432.03	116,704	4
2025-03-13	Slingsby, Brian Taylor, C…	TenPercentOwner	-	Indirect	Purchase	259,259	13.50	$3,499,996.50	8,903,838	4
2025-03-13	Akkaraju, Srinivas	Director	-	Indirect	Purchase	600,000	13.50	$8,100,000.00	5,674,916	4
2025-03-13	Ra, Capital Nexus Fund Ii…	Director	-	Indirect	Purchase	1,296,296	13.50	$17,499,996.00	4,280,051	4
2025-03-13	Samsara, Biocapital, L.P.…	TenPercentOwner	-	Indirect	Purchase	600,000	13.50	$8,100,000.00	5,674,916	4
2025-01-13	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	18,333	9.06	$166,096.98	877,608	4
2025-01-13	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,757	9.36	$100,685.52	226,097	4
2024-11-11	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	5,026	15.00	$75,390.00	140,991	4
2024-11-06	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	25,482	15.03	$382,994.46	135,974	4
2024-10-11	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,757	13.57	$145,972.49	236,854	4
2024-10-11	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	15,271	13.52	$206,463.92	895,941	4
2024-07-24	Slingsby, Brian Taylor, C…	TenPercentOwner	-	Indirect	Sale	550,000	13.05	$7,177,500.00	8,644,579	4
2024-07-16	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	525	15.00	$7,875.00	102,873	4
2024-07-11	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	15,746	13.34	$210,051.64	911,212	4
2024-07-11	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	10,757	13.14	$141,346.98	247,611	4
2024-06-20	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	14,940	11.73	$175,246.20	926,958	4
2024-06-14	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Sale	16,229	12.52	$203,187.08	976,271	4
2024-06-11	Levy, Adam Scott	Officer	CFO and Secretary	Direct	Sale	96,815	12.94	$1,252,786.10	255,462	4
2024-05-09	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	100	15.00	$1,500.00	66,997	4
2024-02-12	Samsara, Biocapital, L.P.…	TenPercentOwner	-	Indirect	Purchase	555,555	13.50	$7,499,992.50	5,074,916	4
2023-11-22	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Purchase	4,250	5.97	$25,372.50	1,049,068	4
2023-09-06	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Purchase	2,250	12.08	$27,180.00	1,044,818	4
2023-08-17	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Purchase	2,250	12.10	$27,225.00	1,042,568	4
2023-08-11	Congleton, Jon	Director,Officer	Chief Executive Officer	Direct	Purchase	2,000	12.89	$25,780.00	1,040,318	4
2023-08-11	Rodman, David Malcom	Officer	Chief Medical Officer	Direct	Sale	157,091	12.81	$2,012,335.71	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

106.09%

Inst. Shares: 87,876,903

Shares Outstanding: 82,834,752

2025-12-31

127.62%

Inst. Shares: 86,342,894

Shares Outstanding: 67,656,355

2025-09-30

112.11%

Inst. Shares: 79,146,601

Shares Outstanding: 70,594,504

2025-06-30

99.54%

Inst. Shares: 65,149,822

Shares Outstanding: 65,451,297

2025-03-31

113.71%

Inst. Shares: 60,449,987

Shares Outstanding: 53,163,551

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	87,876,903	82,834,752	106.09%
2025-12-31	86,342,894	67,656,355	127.62%
2025-09-30	79,146,601	70,594,504	112.11%
2025-06-30	65,149,822	65,451,297	99.54%
2025-03-31	60,449,987	53,163,551	113.71%
2024-12-31	46,368,140	48,539,795	95.53%
2024-09-30	44,307,264	49,815,186	88.94%
2024-06-30	43,834,772	49,356,287	88.81%
2024-03-31	41,668,004	44,900,755	92.80%
2023-12-31	34,546,065	36,188,254	95.46%
2023-09-30	26,244,137	39,930,748	65.72%
2023-06-30	24,983,360	39,754,981	62.84%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Mineralys Therapeutics, Inc. (MLYS) — SEC Financial Statements & Analysis

Mineralys Therapeutics, Inc. (MLYS) is a pharmaceutical preparations company. Mineralys Therapeutics, Inc. trades on Nasdaq as: MLYS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Mineralys Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.04x, a Price-to-Book (P/B) ratio of 4.15x (TTM), at a market cap of $2.29B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.04x
P/B TTM: 4.15x
Market Cap: $2.29B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Mineralys Therapeutics, Inc. in?

Mineralys Therapeutics, Inc. (MLYS) operates in the Pharmaceutical Preparations industry.

What is MLYS's market cap?

Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of $2.29B as of 2026-06-30.

What exchange does MLYS trade on?

Mineralys Therapeutics, Inc. (MLYS) trades on the Nasdaq.